- Home
- PNW vs EXAS Comparison
PNW vs EXAS Comparison
Compare PNW & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNW
- EXAS
- Stock Information
- Founded
- PNW 1985
- EXAS 1995
- Country
- PNW United States
- EXAS United States
- Employees
- PNW N/A
- EXAS N/A
- Industry
- PNW Electric Utilities: Central
- EXAS Medical Specialities
- Sector
- PNW Utilities
- EXAS Health Care
- Exchange
- PNW Nasdaq
- EXAS Nasdaq
- Market Cap
- PNW 10.7B
- EXAS 10.7B
- IPO Year
- PNW N/A
- EXAS N/A
- Fundamental
- Price
- PNW $91.45
- EXAS $51.91
- Analyst Decision
- PNW Buy
- EXAS Strong Buy
- Analyst Count
- PNW 10
- EXAS 20
- Target Price
- PNW $95.00
- EXAS $70.26
- AVG Volume (30 Days)
- PNW 1.3M
- EXAS 2.8M
- Earning Date
- PNW 08-06-2025
- EXAS 07-30-2025
- Dividend Yield
- PNW 3.92%
- EXAS N/A
- EPS Growth
- PNW 8.99
- EXAS N/A
- EPS
- PNW 4.99
- EXAS N/A
- Revenue
- PNW $5,205,483,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- PNW $3.77
- EXAS $14.58
- Revenue Next Year
- PNW $5.85
- EXAS $12.75
- P/E Ratio
- PNW $18.23
- EXAS N/A
- Revenue Growth
- PNW 10.69
- EXAS 11.57
- 52 Week Low
- PNW $78.93
- EXAS $39.97
- 52 Week High
- PNW $96.50
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- PNW 54.76
- EXAS 44.34
- Support Level
- PNW $88.90
- EXAS $52.00
- Resistance Level
- PNW $91.66
- EXAS $55.90
- Average True Range (ATR)
- PNW 1.26
- EXAS 2.31
- MACD
- PNW 0.25
- EXAS -0.04
- Stochastic Oscillator
- PNW 78.82
- EXAS 24.90
About PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases more than 6 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.